- Home
- LI vs MRNA Comparison
LI vs MRNA Comparison
Compare LI & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LI | MRNA |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | China | United States |
| Employees | 30728 | N/A |
| Industry | Auto Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.3B | 21.5B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | LI | MRNA |
|---|---|---|
| Price | $17.66 | $47.12 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 10 | 12 |
| Target Price | $19.66 | ★ $34.27 |
| AVG Volume (30 Days) | 2.6M | ★ 5.1M |
| Earning Date | 05-28-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,263,000,000.00 |
| Revenue This Year | $18.98 | $9.36 |
| Revenue Next Year | $22.72 | $15.43 |
| P/E Ratio | $29.50 | ★ N/A |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $15.71 | $22.28 |
| 52 Week High | $32.03 | $59.55 |
Technical Indicators
Market Signals| Indicator | LI | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 43.28 | 37.58 |
| Support Level | $17.45 | $23.52 |
| Resistance Level | $18.94 | $55.36 |
| Average True Range (ATR) | 0.33 | 2.68 |
| MACD | -0.11 | -0.63 |
| Stochastic Oscillator | 20.29 | 2.86 |
Price Performance
Historical ComparisonAbout LI Li Auto Inc.
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 400,000 NEVs in 2025, accounting for about 3% of China's passenger new energy vehicle market. Beyond Li One, the company expands its product line, including both BEVs and PHEVs, to target a broader consumer base.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.